Covid-19: WHO recommendation on Merck’s oral pill likely in early February

The health body will also review Pfizer's oral pill

By Reuters

Published: Fri 14 Jan 2022, 2:51 PM

The World Health Organisation (WHO) is currently reviewing Merck’s Covid-19 antiviral oral pill molnupiravir and a recommendation will likely be made by early February, an agency official said on Friday.

Janet Diaz, WHO lead on clinical management, said the WHO’S Guidelines Development Group is also getting ready to review Pfizer’s oral pill.

“We will be looking at that (Pfizer oral pill) data in early February for publication likely at the end of that month.”

Late on Thursday, a WHO panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for Covid-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.


Talking about monoclonal antibody treatments, Diaz said some monoclonals are showing impaired neutralisation against the highly infectious Omicron and may be less effective against it.

However, she said it was not a ‘game changer’ as multiple therapeutic options are currently available for Covid-19.

“We are also monitoring antivirals for development of resistance.”

More news from
The richness of accent: Bane or blessing?


The richness of accent: Bane or blessing?

Like any other language, English has changed over time. The accent in which it is spoken is key to how someone is viewed, influenced by many factors: country or region of origin, social and educational background, working environment, friends, and your own sense of identity